EFFICACY AND SAFETY OF COMBINED ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH RENOPARENCHYMAL ARTERIAL HYPERTENSION IN ACTUAL CLINICAL PRACTICE

• Main Authors: N. J. Borovkova, N. N. Borovkov, T. I. Maslov
• Format: Article
• Language: English
• Published: Stolichnaya Izdatelskaya Kompaniya 2016-01-01
• Series: Racionalʹnaâ Farmakoterapiâ v Kardiologii
• Subjects: ренопаренхиматозная артериальная гипертензия; хронический гломерулонефрит
• Online Access: http://www.rpcardio.ru/jour/article/view/684
• ISSN: 1819-6446; 2225-3653

<p><strong>Aim.</strong> To evaluate efficacy and safety of combined antihypertensive therapy based on ramipril, metoprolol tartrate, amlodipine bensilate and rilmenidine dihydrogen phosphate in hypertensive patients with chronic glomerulonephritis (CGN) and normal renal function.</p><p><strong>Material and methods.</strong> 136 patients (39,2±14,6 y.o.) with hypertensive type of primary CGN and with normal renal function were examined. Clinical blood pressure (BP) and 24-hour ambulatory BP monitoring (ABPM) were evaluated initially and in 12 months of antihypertensive therapy.</p><p><strong>Results.</strong> Significant decrease of clinical BP was observed in 12 months of therapy in all patients. Target BP level was reached in 37 % of patients. ABPM indices were also improved: average BP levels and hypertensive burden time decreased, speed of morning BP raise was slow down, there was a tendency to 24-hour BP rhythm improvement. Tolerability of combined therapy was good.</p><p><strong>Conclusion.</strong> The combined antihypertensive therapy based on ramipril, metoprolol tartrate, amlodipine bensilate, rilmenidine dihydrogen phosphate showed good efficacy and safety in hypertensive patients with CGN and normal renal function.</p>